XML 29 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Inventories
 12 Months Ended
Dec. 31, 2022
Inventory Disclosure [Abstract]  
Inventories Inventories
The Company's net inventories consisted of the following as of December 31:
20222021
Raw materials and work in process, net of reserve$12,899,659 $12,374,983 
Consigned inventory168,923 164,378 
Finished goods, net of reserve4,322,167 4,939,088 
Total inventories17,390,748 17,478,449 
less non-current inventories(7,527,167)(9,048,567)
Total inventories classified as current$9,863,581 $8,429,882 
At December 31, 2022 and 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.5 million and $1.4 million, respectively.
In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at December 31, 2022 and 2021. Consigned inventory represents Authorized Generic inventory stored with Padagis until shipment.
As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were classified as non-current inventories. The Vibativ non-current API inventory was $7.1 million at December 31, 2022 and $8.1 million at December 31, 2021. The Company had no Vibativ finished goods included in the non-current inventories at December 31, 2022, and $0.5 million at December 31, 2021. At December 31, 2022 and 2021, Cumberland had $0.3 million in non-current inventory for API related to its ifetroban clinical initiatives and $0.1 million of finished goods